Emerging entities in NUTM1-rearranged neoplasms

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• NUTM1 alterations were initially linked to midline carcinomas (NUT carcinomas) with a specific BRD4-NUTM1 gene fusion.
• Next-generation sequencing has expanded the spectrum of NUTM1 alterations beyond carcinomas.

Purpose of the Study:

• To provide an overview of the molecular, nosological, and clinical features of newly discovered NUTM1-rearranged neoplasms (NRNs).
• To explore the oncogenic mechanisms and clinical implications of diverse NUTM1 fusion partners.

Main Methods:

• DNA and RNA-based next-generation sequencing to identify NUTM1 fusion partners.
• Analysis of molecular, nosological, and clinical data from various neoplasms with NUTM1 rearrangements.

Main Results:

• Identification of numerous new NUTM1 fusion partners in diverse neoplasms, including sarcomas, poromas, and acute lymphoblastic leukemias (ALLs), termed NRNs.
• Correlation between the functional classification of fusion partners and NRN nosology, suggesting distinct oncogenic pathways.
• Observed differences in clinical aggressiveness and therapeutic response among NRNs, linked to specific fusion partners.

Conclusions:

• Aberrant NUTM1 expression via fusion proteins acts as a potent chromatin modifier, driving oncogenesis across various cellular contexts.
• NUTM1 fusion partner is a more critical determinant of NRN classification, behavior, and treatment than morphology or immunohistochemistry.